AGP Executive Report

Heat & Cooling: Europe’s 2003 heatwave killed 20,000+ and records are being broken again this year, yet only ~20% of Europeans have air conditioning versus ~90% in the US—raising pressure on hospitals, schools, and outdoor work planning. Border Tech & Travel Ops: The EU Entry/Exit System (EES) is driving queues and calls to pause it during peak summer, with Schengen countries (including Liechtenstein) using biometrics for non-EU travellers and airports warning of major disruption. Crypto Regulation Shift: With MiCA’s July 1 deadline, the EU/EEA is set to squeeze out unauthorized crypto firms; only 244 of 3,000+ registered providers reportedly secured licenses, pushing migration toward lighter-touch hubs like Dubai. Liechtenstein in Finance: Sygnum says its Liechtenstein-based CASP licence under MiCAR gives it direct EU access as it scales EU operations. Pharma Pipeline: SERB completed rights acquisition for Idefirix® (imlifidase) covering EU/UK/Switzerland and Liechtenstein, while Neuren’s DAYBU (trofinetide) gained a positive CHMP opinion for Rett syndrome in the EU. Trade & Industry: The EU moves to cut steel imports via a tariff-free quota system, while the UK consolidates dual-use export licensing into a new OGEL to reduce paperwork. AI in Finance: Research warns that widespread AI trading could crowd markets, shorten signal lifespans, and increase systemic risk.

MiCA Shockwave for Crypto: With the MiCA transition ending July 1, EU/EEA access is tightening fast—only 244 of 3,000+ prior registrants reportedly secured licenses, and OKX’s CEO expects up to 80% of firms to exit. Liechtenstein as a Gateway: Sygnum is scaling EU access via a Liechtenstein-based CASP/MiCAR setup, positioning the principality as a regulated bridge into the bloc. Cross-Border Travel Friction: Europe’s new Entry/Exit System (EES) is driving fresh airport warnings about summer border delays, and families are being told to prepare for child biometrics and longer queues. Private Banking Tech Moves: Objectway is buying FNZ’s Swiss private banking technology unit, expanding its footprint across Switzerland and Liechtenstein. Healthcare & Pharma Uptick: SERB completed rights acquisition for Idefirix (imlifidase) covering EU/UK/Switzerland and Liechtenstein, while Merck won EU approval for Keytruda+Padcev in cisplatin-ineligible bladder cancer and Neuren’s DAYBU gained a positive CHMP opinion for Rett syndrome. Trade Pressure on Industry: The EU is preparing steel import quota changes tied to “alliance” partners, and Brussels is weighing anti-subsidy tariffs on Chinese plug-in hybrids.

MiCA Deadline Shock for Crypto: With July 1 ending the EU transition, Liechtenstein-licensed crypto firms are moving into full operating mode while many unlicensed providers face a squeeze; Sygnum Europe says its Liechtenstein CASP licence now gives it direct EU/EEA access for private wealth and institutions, as the broader market braces for major contraction. EU Trade Protection for Industry: Brussels is preparing tariff-free steel import quotas that favor existing free-trade partners, while also weighing wider tariff moves that could hit Chinese plug-in hybrid growth. Healthcare Innovation in the EU/EEA: The EU has approved Merck’s perioperative KEYTRUDA plus Padcev regimen for cisplatin-ineligible muscle-invasive bladder cancer, extending a new option across EU states plus Iceland, Liechtenstein and Norway. Cross-Border Compliance & Mobility: The EU’s Entry/Exit System is rolling out for non-EU travelers to Schengen, with Liechtenstein included, meaning more biometric processing at borders this summer. Finance & Risk Management: OpenPayd secured MiCA authorization to offer regulated crypto services across the EEA, signaling how quickly regulated infrastructure is becoming the new baseline.

MiCA Push for Liechtenstein Finance: Sygnum Europe (licensed in Liechtenstein) is moving into full EU/EEA operating mode after its CASP authorisation, using its Swiss/Singapore banking platform to expand access for private wealth and institutions as the July 1 MiCA deadline ends the transition. Crypto Compliance Deadline Pressure: With MiCA set to cut off unauthorised crypto providers, firms are scrambling for licences; estimates suggest only a fraction of Europe’s registered providers will make it through, while some are already looking to the UAE for faster market entry. EU Trade Shield for Industry: The European Commission is proposing tariff-free steel import quotas to protect the metals sector, with higher duties for over-quota volumes and allocation rules favoring existing free-trade partners. Cross-Border Healthcare Clarity: A practical guide explains how EU cross-border healthcare works, including when prior authorisation applies and how costs are handled—relevant for Liechtenstein residents traveling for treatment. EU Approves New Bladder Cancer Regimen: The EU has approved Merck’s KEYTRUDA plus Padcev perioperative treatment for cisplatin-ineligible muscle-invasive bladder cancer, extending options across EU member states plus Iceland, Liechtenstein and Norway.

MiCA Push in Liechtenstein Finance: Sygnum says its Liechtenstein-based unit has secured a MiCA licence, giving it direct access to EU and EEA clients as the July 1 transition deadline nears. The firm is positioning its bank-to-bank infrastructure, custody and digital asset products for private wealth and institutions. MiCA Deadline Shock: Separate coverage warns that MiCA’s end of transition could squeeze out most crypto providers: only 244 of 3,000+ prior registrants reportedly completed authorisation, with compliance costs potentially reaching hundreds of thousands of euros. New MiCA Licences Across Europe: OpenPayd also won MiCA authorisation for EEA-wide stablecoin and custody services, while Bitcoin Suisse (Europe) received a MiCAR licence from Liechtenstein’s Financial Market Authority to expand trading, custody and staking. Cross-Border Healthcare Basics: A practical explainer breaks down how EU cross-border care works, including when prior authorisation applies and how costs are handled. EU Border Tech for Summer Travel: The Entry/Exit System (EES) is rolling out for non-EU travellers to Schengen, with biometrics replacing passport stamping and longer waits expected at peak times. EU Approvals for Cancer Care: The EU approved KEYTRUDA plus Padcev for cisplatin-ineligible muscle-invasive bladder cancer, and Trodelvy for first-line metastatic triple-negative breast cancer in eligible patients.

MiCA Deadline Shock: With the July 1 transition ending, Europe’s MiCA rules are set to squeeze out most crypto firms—only 244 of 3,000+ earlier registrants reportedly secured licenses, and compliance costs can hit hundreds of thousands of euros. Liechtenstein Crypto Boost: Bitcoin Suisse (Europe) AG received a MiCAR Crypto Asset Service Provider license from Liechtenstein’s FMA, giving it a regulated base for EEA trading, custody and staking expansion. Payments Infrastructure: OpenPayd also secured MiCA authorization, enabling regulated fiat-to-stablecoin conversions, custody and stablecoin transfers across the EEA via a single license. EU Health Approvals: CHMP backed DAYBU (trofinetide) for Rett syndrome symptoms, and the EU approved perioperative KEYTRUDA plus Padcev for cisplatin-ineligible muscle-invasive bladder cancer. Energy Transition Watch: Offshore wind is being positioned as Asia’s next big investment frontier, with the Philippines highlighted for its coastal wind potential. Travel Rules for the Region: The EU’s Entry/Exit System (EES) will replace passport stamping for non-EU travelers, with Liechtenstein included in the Schengen coverage.

Crypto Regulation in Liechtenstein: Bitcoin Suisse (Europe) AG received a MiCAR Crypto Asset Service Provider license from Liechtenstein’s FMA, giving it a regulated base to serve selected EEA markets with trading, custody and staking. EU Financial Services: OpenPayd also secured MiCA authorization, enabling regulated fiat-to-stablecoin conversions, custody and stablecoin transfers across the EEA via a single API. Healthcare & Pharma (EU-wide, incl. Liechtenstein): Merck won EU approval for KEYTRUDA + Padcev as perioperative treatment for cisplatin-ineligible adults with resectable muscle-invasive bladder cancer, and Gilead’s Trodelvy gained EU marketing authorization for first-line metastatic TNBC ineligible for PD-1/PD-L1 therapy (also covering Norway, Iceland and Liechtenstein). Energy Transition: Offshore wind is being positioned as Asia’s next investment frontier, with the Philippines highlighted for its coastal wind potential and energy-security push. Local Industry & Trade: Liechtenstein Post’s role featured in the Macao 2026 stamp exhibition opening, underscoring how small-country craftsmanship still reaches global audiences.

Water Infrastructure Watch: A new global map highlights that over 2 billion people still lack safely managed drinking water, with access near-universal in parts of Europe and North America but below 20% in several low-income countries, underscoring ongoing pressure for water-system upgrades. Liechtenstein Finance & Crypto Regulation: Bitcoin Suisse (Europe) AG received a MiCAR Crypto Asset Service Provider license from Liechtenstein’s FMA, giving it a regulated base to expand crypto trading, custody and staking across selected EEA markets. EU Pharma Approvals (Liechtenstein included): The European Commission approved KEYTRUDA + Padcev as a perioperative option for cisplatin-ineligible resectable muscle-invasive bladder cancer, and DAYBU (trofinetide) gained a positive CHMP opinion for Rett syndrome neurobehavioral symptoms—both relevant for Liechtenstein patients via EU-wide authorization. Offshore Wind Investment: A report points to the Philippines emerging as an offshore wind investment frontier, driven by energy security and high coastal wind potential. Cross-border Legal Risk: An Ontario court ruling allowed fraud claims to proceed against a Liechtenstein-based trustee, reinforcing how cross-border disputes can hinge on where money was taken.

Liechtenstein Trust in Spotlight: A new UK investigation claims Oxford accepted donations tied to Max Mosley’s fortune, including allegations that the money flowed through a secretive Liechtenstein trust—raising fresh questions about how offshore structures can mask controversial origins. EU Pharma Approvals: The EU is moving forward with new cancer and rare-disease treatments that also cover Liechtenstein: Merck’s perioperative KEYTRUDA plus Padcev regimen for cisplatin-ineligible muscle-invasive bladder cancer, and Gilead’s Trodelvy first-line metastatic triple-negative breast cancer approval; separately, Acadia’s DAYBU (trofinetide) received a positive CHMP opinion for Rett syndrome. Crypto Regulation, Liechtenstein Included: Bitcoin Suisse (Europe) AG secured a MiCAR CASP license from Liechtenstein’s FMA, while OpenPayd also obtained MiCA authorization to expand regulated stablecoin services across the EEA. Cross-Border Finance & Courts: An Ontario court cleared fraud claims to proceed against a Liechtenstein-based trustee in a Bridging Finance dispute, focusing on whether Ontario has jurisdiction over alleged misappropriation. Industry & Energy: The Philippines is being pitched as an offshore wind investment frontier, and Liechtenstein Post highlighted its stamp culture at Macao 2026’s “Stamp Day.”

EMA Watch: Acadia’s DAYBU® (trofinetide) cleared a CHMP positive opinion for marketing authorization in the EU for neurobehavioral symptoms of Rett syndrome in adults and children aged five and up, with the European Commission decision still pending. EU Oncology: Merck’s KEYTRUDA + Padcev perioperative regimen won EU approval for adults with resectable muscle-invasive bladder cancer who can’t receive cisplatin, extending across all 27 EU states plus Iceland, Liechtenstein and Norway. Liechtenstein Finance & Crypto: Bitcoin Suisse (Europe) AG received a MiCAR Crypto Asset Service Provider license from Liechtenstein’s FMA, giving it a regulated base to expand crypto trading, custody and staking across selected EEA markets. Cross-border Lending: An Ontario court allowed fraud claims to proceed against a Liechtenstein-based trustee, ruling the dispute has a real and substantial connection to Ontario. Energy & Industry Context: A report highlights offshore wind as a growing investment target for the Philippines, driven by energy security and long-term cost advantages. Trade & Mobility: New EU border rules via the Entry Exit System (EES) may slow Schengen arrivals for non-EU travelers, including those entering via Liechtenstein.

Rett syndrome drug push: Acadia’s DAYBU® (trofinetide) cleared a positive CHMP re-examination opinion for neurobehavioral symptoms of Rett syndrome in EU patients aged five and up, with EU Commission approval still pending. Bladder cancer treatment update: The European Commission approved Merck’s perioperative KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin) for adults with resectable muscle-invasive bladder cancer who can’t receive cisplatin, extending the option across EU27 plus Iceland, Liechtenstein and Norway. Liechtenstein finance in focus: Bitcoin Suisse (Europe) AG received a MiCAR Crypto Asset Service Provider license from Liechtenstein’s FMA, giving it a regulated base for trading, custody and staking across parts of the EEA. Crypto licensing momentum: OpenPayd also secured MiCA authorization to offer regulated fiat-to-stablecoin conversions, custody and stablecoin transfers across the EEA ahead of the July 1 deadline. Industry & trade backdrop: A major EU product liability overhaul is moving toward a December 2026 transposition deadline, reshaping risk for manufacturers and digital supply chains. Local relevance: Liechtenstein Post’s role in the Macao 2026 stamp exhibition highlighted the principality’s cultural and production craftsmanship on an international stage.

Offshore Wind Push: The Philippines is positioning itself as Asia’s offshore wind investment frontier, citing energy security pressures and a lower long-term cost path, with GWEC’s 2026 report and Manila events highlighting policy and infrastructure needs. EU Oncology Update: Merck won EU approval for a perioperative KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin) regimen for cisplatin-ineligible resectable muscle-invasive bladder cancer, with KEYNOTE-905 data showing major reductions in recurrence and death risk. Liechtenstein in the Crypto Spotlight: Bitcoin Suisse (Europe) AG received a MiCAR Crypto Asset Service Provider license from Liechtenstein’s FMA, giving a regulated base for trading, custody and staking across selected EEA markets. MiCA Expansion in Europe: OpenPayd also secured MiCA authorization to offer regulated fiat-to-stablecoin conversions, custody and stablecoin transfers across the EEA ahead of the July 1 deadline. Cross-Border Finance Watch: A Canadian court case over Bridging Finance fraud turned on whether Ontario courts can hear claims against a Liechtenstein-based trustee, with the court finding a real and substantial Ontario connection. EU Security & Liability: The European Commission proposed stronger Europol/Eurojust mandates for cross-border crime and updated the EU product liability directive landscape, raising compliance and litigation exposure for manufacturers and digital supply chains. Trade & Energy Context: EU/FTA and trade diversification themes also surfaced, alongside broader energy-cost pressure signals tied to diesel price swings.

Global Trade & FTAs: Thailand’s commerce push is reshaping supply chains as firms diversify to cut geopolitical risk, while the country expands its FTA network—adding an EFTA deal (including Liechtenstein) expected by 2027 and negotiating an EU FTA. EU Security & Justice: The European Commission proposes stronger Europol and Eurojust mandates plus updates to the European Investigation Order and data rules to speed cross-border prosecutions against serious crime and terrorism. Crypto Regulation (Liechtenstein-linked): Bitcoin Suisse (Europe) AG received a MiCAR Crypto Asset Service Provider license from Liechtenstein’s FMA, giving a regulated base for EEA expansion; OpenPayd also secured MiCA authorization for stablecoin and custody services across the EEA. Healthcare (Liechtenstein included): The EU approved KEYTRUDA plus Padcev as a perioperative option for cisplatin-ineligible muscle-invasive bladder cancer, and Trodelvy for first-line metastatic TNBC. Cross-border Lending Rules: CRD VI’s licensed branch requirement for third-country lenders takes effect from 11 Jan 2027, with documentation implications for cross-border loans. Industry Skills: Liechtenstein Development Fund support backs Moldova vocational schools and dual education partnerships tied to energy, transport, construction, and food services.

EU Security Push: The European Commission proposes stronger cross-border tools for serious crime and terrorism, including new mandates for Europol and Eurojust, a revised European Investigation Order, and updates to data rules for EU bodies. Healthcare & Pharma Access: The European Commission approved KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin) for cisplatin-ineligible resectable muscle-invasive bladder cancer, and also cleared Trodelvy (sacituzumab govitecan) for first-line metastatic triple-negative breast cancer in the EU—both valid in Liechtenstein. Crypto Regulation in Liechtenstein’s Orbit: Bitcoin Suisse (Europe) received a MiCAR Crypto Asset Service Provider license from Liechtenstein’s FMA, while OpenPayd secured MiCA authorization across the EEA—signals more regulated digital-asset services for regional finance. Border & Consumer Impact: The Schengen Entry Exit System (EES) is set to affect first trips into the area, with extra processing time and biometric capture for non-EU travellers, including Liechtenstein. Industry Compliance Watch: The revised EU Product Liability Directive is moving toward a December 2026 transposition deadline, with rising litigation exposure for manufacturers and digital supply chains.

MiCAR Expansion in Liechtenstein: Bitcoin Suisse (Europe) AG received a Crypto Asset Service Provider license from Liechtenstein’s Financial Market Authority, giving the group a regulated base to serve selected EEA markets with trading, custody and staking. Crypto Infrastructure Push: OpenPayd also secured MiCA authorization, enabling regulated fiat-to-stablecoin conversions, custody, wallet infrastructure and stablecoin transfers across the EEA ahead of the July 1 deadline. EU Crime & Data Rules: The European Commission proposed stronger mandates for Europol and Eurojust plus updates to the European Investigation Order and data protection rules for EU bodies, aiming to speed cross-border investigations. EU Product Liability Overhaul: The revised EU Product Liability Directive (transposition by Dec 9, 2026) is set to reshape litigation risk for digital and software supply chains via claimant-friendly presumptions and disclosure duties. Schengen Travel Reality Check: Liechtenstein-linked Schengen coverage highlights the Entry Exit System (EES), warning first trips may take longer as non-EU travellers provide biometrics. Healthcare in the EEA: The EU approved KEYTRUDA plus Padcev as perioperative treatment for cisplatin-ineligible resectable muscle-invasive bladder cancer, and Trodelvy for first-line metastatic triple-negative breast cancer. Green Trade Partnerships: Norway’s ambassador to India hailed a “green strategic partnership” focused on green energy, maritime industries and circular economy, alongside EFTA trade milestones. Energy & Freight Pressure: A global diesel-price map notes diesel’s link to freight, agriculture and construction—useful context as markets react to geopolitical shocks.

EU Product Liability: The European Commission’s revised Product Liability Directive is nearing its Dec 9, 2026 transposition deadline, with draft laws already showing different national interpretations—raising strict, no-fault claim risk for manufacturers, importers and digital platforms across cross-border supply chains. Healthcare & Pharma: The EU approved KEYTRUDA plus Padcev as a perioperative option for cisplatin-ineligible resectable muscle-invasive bladder cancer, and Trodelvy received first-line EU authorization for certain metastatic triple-negative breast cancer patients. Security & Justice: Brussels proposed stronger Europol/Eurojust mandates plus updates to the European Investigation Order and data rules to speed cross-border prosecutions against digital and cross-border crime. Crypto Regulation (Liechtenstein-linked): Bitcoin Suisse (Europe) gained a MiCAR CASP license from Liechtenstein’s FMA, while OpenPayd secured MiCA authorization to expand regulated stablecoin services across the EEA. Cross-border Industry Watch: Norway and India announced a “green strategic partnership” focused on green energy, maritime industries and circular economy, with trade talks also in view. Border Operations: The Schengen Entry Exit System (EES) is set to affect summer travel timing for non-EU visitors, including Liechtenstein’s Schengen border context.